Report overview
This report contains market size and forecasts of Pulmonary Arterial Hypertension (PAH) Drugs in global, including the following market information:
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Pulmonary Arterial Hypertension (PAH) Drugs companies in 2021 (%)
The global Pulmonary Arterial Hypertension (PAH) Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Inhalation Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs include Pfizer, Glaxosmithkline, Novartis, United Therapeutics, AstraZeneca, Merck, Bayer Healthcare, Actelion Pharmaceuticals and Daiichi Sankyo, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Pulmonary Arterial Hypertension (PAH) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pulmonary Arterial Hypertension (PAH) Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment Percentages, by Type, 2021 (%)
Inhalation
Injectables
Oral Administration
Global Pulmonary Arterial Hypertension (PAH) Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Other
Global Pulmonary Arterial Hypertension (PAH) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pulmonary Arterial Hypertension (PAH) Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Pulmonary Arterial Hypertension (PAH) Drugs revenues share in global market, 2021 (%)
Key companies Pulmonary Arterial Hypertension (PAH) Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Pulmonary Arterial Hypertension (PAH) Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Glaxosmithkline
Novartis
United Therapeutics
AstraZeneca
Merck
Bayer Healthcare
Actelion Pharmaceuticals
Daiichi Sankyo
Northern Therapeutics
Aires Pharmaceuticals
Arena Pharmaceuticals
Berlin Cures
Eiger BioPharmaceuticals
Reata Pharmaceuticals
